Chronic lymphocytic leukaemia: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

24 of 25+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Czechia· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Oct 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Translating Epigenetic Memory into Personalized Prognostic Solutions for Chronic Lymphocytic Leukemia (TEMPLe)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Jun 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the life histories of chronic lymphocytic leukemia to improve clinical outcome (CLL-STORY)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €1,827,291· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Making patient-derived tumor organoids a reliable cancer therapy testing platform (TUMORGPLAT)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €245,490· until Dec 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across Europe (RESOLVE)

  Martin-Luther-Universitat Halle-Wittenberg· Halle, Germany· EU contribution €8,000,000· until Mar 2029· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  COmputational DEsign for 4D BIOfabrication: harnessing programmable materials for dynamic pre-clinical cancer models (CoDe4Bio)

  Universita Degli Studi di Pavia· Pavia, Italy· EU contribution €1,495,100· until Dec 2027

  The disease is named only in the funder's project summary, not in the title.

10 of 11 running projects, newest first. Listed amounts together: €16.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Suspended

  Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

  NCT06662227· Wondercel Biotech (ShenZhen)· Updated 7 May 2026

  “Because the implementation of the new regulation policy by the Chinese authority”Registry text, quoted unchanged. Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Incyte Corporation· Updated 4 Feb 2026

  “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”Registry text, quoted unchanged. Source

• Terminated

  Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT06343376· Roswell Park Cancer Institute· Updated 3 Aug 2025

  “Manufacturing issues”Registry text, quoted unchanged. Source

• Terminated

  CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

  NCT05094206· Medical College of Wisconsin· Updated 19 Sept 2024

  “Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

  NCT06205290· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Updated 2 Apr 2024

  “Business objectives have changed.”Registry text, quoted unchanged. Source

• Withdrawn

  Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

  NCT03098355· Zhujiang Hospital· Updated 18 Mar 2024

  “The company did not offer the appropriate CART services.”Registry text, quoted unchanged. Source

• Withdrawn

  CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

  NCT05613348· Zhujiang Hospital· Updated 18 Mar 2024

  “The company failed to provide corresponding CART services.”Registry text, quoted unchanged. Source

• Withdrawn

  Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

  NCT05037669· University of Pennsylvania· Updated 22 Jun 2023

  “No available investigational product”Registry text, quoted unchanged. Source

• Withdrawn

  Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

  NCT05570188· Kunming Hope of Health Hospital· Updated 30 Nov 2022

  “The PI decides to stop.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

  NCT01087294· National Cancer Institute (NCI)· Source

• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  NCT05442515· National Cancer Institute (NCI)· Source

• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  NCT06364423· National Cancer Institute (NCI)· Source

• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

  NCT05797233· National Cancer Institute (NCI)· Source

• Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

  NCT04732845· Benjamin Tomlinson· Source

• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

  NCT04464200· Memorial Sloan Kettering Cancer Center· Source

• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Incyte Corporation· Source

• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

  NCT03448393· National Cancer Institute (NCI)· Source

• Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

  NCT06961669· Anhui Provincial Hospital· Source

• CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

  NCT06834529· Affiliated Hospital to Academy of Military Medical Sciences· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• Sequential versus Simultaneous Quantitative Analysis of Biomarkers in Individual Cells by ICP-MS and Mass Cytometry: A Focus on Immunotherapy.

  Anal Chem, Nov 2025

• Fludarabine metabolism by cytosolic 5'-nucleotidase III and its tissue-specific localization mapping using mass spectrometry imaging.

  Drug Metab Dispos, Oct 2025

See which targets of this disease your abstract mentions, and go to the people working on them.